is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The fight against bacteria that are resistant to antibiotics is a crucial element of medical and microbiological research today. The phenomenon of antibiotic resistance itself is a part of the expression of the bacterial genome, and therefore can be expected to emerge in whatever situation antibiotics are used, and to increase with the number of drugs used.
Over the last two decades multi-drug resistant microorganisms (MDROs) have been increasing in frequency and diversity. Overuse and misuse of antibiotics, as well as inadequate infection control, have led to the development of resistance and global spread of these organisms.
The introduction of diagnostic tests in clinical practice has been for long based on the work of so-called “expert groups” or “expert panels”, which were in duty of revising applications and updating the list of clinically available tests according to recent biological discoveries, technological developments or changes of disease epidemiology.